XTX Topco Ltd Purchases 22,416 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

XTX Topco Ltd boosted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 66.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,360 shares of the company’s stock after purchasing an additional 22,416 shares during the period. XTX Topco Ltd’s holdings in Cellebrite DI were worth $949,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in CLBT. FMR LLC increased its holdings in Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock worth $94,586,000 after purchasing an additional 3,239,307 shares in the last quarter. Principal Financial Group Inc. bought a new position in Cellebrite DI during the 3rd quarter worth about $23,402,000. Pembroke Management LTD grew its holdings in shares of Cellebrite DI by 104.9% in the 2nd quarter. Pembroke Management LTD now owns 1,535,726 shares of the company’s stock valued at $18,352,000 after acquiring an additional 786,310 shares in the last quarter. Summit Partners Public Asset Management LLC bought a new position in shares of Cellebrite DI in the 3rd quarter valued at about $9,274,000. Finally, Meitav Investment House Ltd. grew its holdings in shares of Cellebrite DI by 29.7% in the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock valued at $34,797,000 after acquiring an additional 473,293 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $19.89 on Wednesday. Cellebrite DI Ltd. has a 52-week low of $7.91 and a 52-week high of $21.72. The company has a market capitalization of $4.10 billion, a P/E ratio of -12.83, a price-to-earnings-growth ratio of 2.91 and a beta of 1.51. The company has a 50-day simple moving average of $18.73 and a 200 day simple moving average of $15.62.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. The firm had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same period last year, the business posted $0.09 earnings per share. As a group, equities analysts forecast that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Craig Hallum raised their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Needham & Company LLC raised their price objective on Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Bank of America raised their price objective on Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Lake Street Capital raised their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI presently has a consensus rating of “Buy” and an average price target of $20.29.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.